×
TuHURA Biosciences EBITDA 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TuHURA Biosciences ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
TuHURA Biosciences EBITDA 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TuHURA Biosciences ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.8B
Vertex Pharmaceuticals (VRTX)
$122.6B
Gilead Sciences (GILD)
$109.8B
Bristol Myers Squibb (BMY)
$107B
Regeneron Pharmaceuticals (REGN)
$106.1B
CSL (CSLLY)
$96.1B
GSK (GSK)
$78.8B
Alnylam Pharmaceuticals (ALNY)
$38.1B
Argenex SE (ARGX)
$34B
Biogen (BIIB)
$27.1B
BioNTech SE (BNTX)
$26.4B
Illumina (ILMN)
$22.9B
BeiGene (BGNE)
$21.5B
Moderna (MRNA)
$20.5B
Genmab (GMAB)
$15.1B
BioMarin Pharmaceutical (BMRN)
$13.4B
Exact Sciences (EXAS)
$13B
Insmed (INSM)
$12.7B
Incyte (INCY)
$12.6B
Vaxcyte (PCVX)
$12.6B
Sarepta Therapeutics (SRPT)
$12.2B
Bio-Techne Corp (TECH)
$11.1B
QIAGEN (QGEN)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.7B
Exelixis (EXEL)
$8.2B
Legend Biotech (LEGN)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Repligen (RGEN)
$8.1B
Revolution Medicines (RVMD)
$7.9B